



IPPC

POST-EVENT

REPORT

20-21 May, 2025 • Warsaw, Poland



IPPC 2025:

Two Decades of Progress Within a Critical Global Plasma Supply Chain

Dear Reader,

The 2025 International Plasma Protein Congress (IPPC), held on 20-21 May in Warsaw, marked a significant milestone: twenty years of convening stakeholders to advance understanding, collaboration, and innovation across the global plasma protein therapies sector. This year's event brought together industry leaders, patient advocates, regulatory officials, and clinical experts for critical discussions on sustainability, donor health, supply chain resilience, and the future of plasma collection worldwide. With thought-provoking panels, a timely and relevant opening session, and active dialogue throughout, IPPC 2025 reinforced the plasma community's shared commitment to ensuring patient access to lifesaving plasma-derived therapies.

As noted in this year's theme – twenty years of progress across a unique and global supply chain – the conversations on stage noted both challenges and opportunities. One thing was clear at the end of our time in Warsaw: There is still much work to be done to increase understanding of plasma donation, the medicines it produces, and the patients who rely on them. And this, we can only achieve by continuing to work together.

Thank you to all who attended and supported this year's IPPC. Your voice shapes our future, and we look forward to continuing the momentum at IPPC 2026 in Milan, Italy.

Sincerely,



Marilena Vrana,
Vice President, Public Affairs & EU Operations

Session Summaries



PLENARY SESSION: TRADE & TARIFFS: TRUMP 2.0 AND ITS EFFECT ON THE PLASMA INDUSTRY: A DISCUSSION OF KEY ISSUES

Speakers explored how recent U.S. trade policy shifts under the Trump administration could influence global plasma supply, regulatory authority, and transatlantic trade relationships.



SESSION 1: PATIENT-DRIVEN PROGRESS – ADVANCING PLASMA-DERIVED MEDICINES & ADDRESSING DISPARITIES

Patient advocates and leaders reflected on 20 years of progress in disease awareness, diagnosis, and access to PDMPs, highlighting persistent disparities and the road ahead for patient-centered policy.



SESSION 2: CRITICAL MEDICINES – EUROPEAN STRATEGIES FOR PREVENTING SHORTAGES AND SECURING SUPPLY

Panelists unpacked EU-led solutions like the ESMP and new legislative reforms to strengthen resilience and avoid PDMP shortages during emergencies.

Session Summaries



SESSION 3: PUSHING BARRIERS – GLOBAL PERSPECTIVES ON IMPROVING PATIENT ACCESS

Experts discussed global disparities in PDMP access and showcase regionally tailored innovations helping patients outside the EU and U.S. receive vital therapies.



SESSION 4: INNOVATION – WHAT'S NEXT FOR PDMPS?


Industry researchers and R&D leaders shared ongoing work to develop new PDMP indications and therapies, spotlighting promising novel applications and clinical pipelines.



SESSION 5: METHODOLOGIES IN DONOR HEALTH AND SAFETY RESEARCH


This session presented cutting-edge research using real-world data to advance global donor safety standards and refine evidence-based donation practices.

Session Summaries




SPECIAL SEGMENT: "IT'S MY MOVIE TIME": HEAR FROM A PLASMA DONOR

A first-person account from a German plasma donor underscored the personal motivations behind donation and how storytelling can strengthen community engagement.



SESSION 6: BUILDING A RESILIENT SUPPLY OF PLASMA FOR FRACTIONATION

Speakers emphasized the value of public-private coexistence, practical SoHO implementation, and sustainable models to future-proof global plasma supply chains.



SESSION 7: ENSURING ACCESS – THE ROLE OF MARKET POLICIES FOR PDMPS

Panelists evaluated how reimbursement systems and mandatory stockpiling shape PDMP access, advocating for a shift from "one-size-fits-all" to patient-tailored policy models.

Attendee Testimonials



In my opinion, anyone who has any connection to the plasma industry has to attend IPPC.

**Santiago Gonzalez,
VP of Corporate Affairs, Global Subsidiaries Governance, Grifols;
PPTA EU Board Director & Treasurer**

IPPC connects the science, the people, and the purpose behind everything that we do in this industry together.

**Jennifer Duven, MD,
Chief Medical Officer & Head of Medical & Regulatory Affairs, Join Parachute**

IPPC gives a great opportunity for industry leaders to come together, share the latest insights, and drive meaningful progress in the plasma industry.

**Shavit Beladev,
Vice President, Kamada Plasma**



By getting together [at IPPC] you are seeing what progress has been made, and I truly believe you need to understand the past to shape the future. So it's important for people to learn what has happened since the last time we met, because things are constantly changing.

**Mary Mallory,
Director, Marketing, Plasma Innovations at Terumo Blood and Cell Technologies**

IPPC is an important enabler for me to follow topics from experts and understand the positions of my external counterparts.

**Atakan Yesil,
Senior Public Affairs Lead, Global Plasma Derived Therapies Business Unit, Takeda**

IPPC 2025 By the Numbers





#IPPC2026

SAVE THE DATE

28 – 29 April • Milan, Italy

Email info@pptaglobal.org
for more information

IG — pptaglobal

X — PlasmaProteins

FB — Plasma Protein Therapeutics Association

LI — plasma-protein-therapeutics-association

